Collaborations & licenses
Our partnering strategy focuses on expanding and accelerating our ability to deliver transformational precision therapies to patients worldwide.
With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are committed to building a robust, industry-leading portfolio of precision therapies based on our proprietary drug discovery platform.
We actively seek collaboration or licensing opportunities that complement our existing portfolio and research focus. If you or your company are interested in partnering opportunities, please contact us.
In March 2016, we entered into a global collaboration with Roche to discover, develop and commercialize up to five small-molecule therapeutics targeting kinases believed to be important in cancer immunotherapy, either as monotherapies or combination therapies. Blueprint Medicines will lead preclinical research and development through Phase 1 proof-of-concept for all five programs, enabling us to accelerate efforts in the emerging field of cancer immunotherapy and to continue building a leading biopharmaceutical company. Under the collaboration, Blueprint Medicines retains U.S. commercialization rights for up to two programs, and Roche has worldwide commercialization rights for up to three programs and ex-U.S. commercialization rights for up to two programs.
In June 2018, we entered into collaboration with CStone Pharmaceuticals to develop and commercialize our three lead clinical-stage therapeutic candidates avapritinib, fisogatinib and pralsetinib in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies. Blueprint Medicines will retain all rights to the licensed products in the rest of the world. The collaboration expands Blueprint Medicines efforts to globally address patient populations with high unmet needs.
In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, for BLU-782, an investigational ALK2 inhibitor being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). Blueprint Medicines designed BLU-782 to selectively target mutant ALK2, the underlying cause of FOP, using our proprietary scientific platform. Ipsen’s global infrastructure and clinical expertise in FOP have the potential to accelerate clinical development of BLU-782 for FOP.